key: cord-0922938-56yey6ka
authors: Smieszek, Sandra P.; Przychodzen, Bart P; Polymeropoulos, Mihael H.
title: “Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment “
date: 2020-04-30
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106004
sha: 1043cb5a53dbd4ba0de1bd1e761c39fc0ed2b7e6
doc_id: 922938
cord_uid: 56yey6ka

Abstract SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-Cov-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes). We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown to downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease. It is available as a generic drug. Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection.

-Cathepsin L (CTSL) disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increased pH in lysosomes). -We have conducted a high throughput drug screen gene expression analysis to identify potential compounds that would down regulate the expression of CTSL/CTSB and found amantadine to be one of the top inhibitors. -Amantadine may act as a lysosomotropic agent and alters the Cathepsin L functional environment. -Amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic agent, decreasing the replication and infectivity of the virus likely, leading to better clinical outcomes -Genetic variants in CTSL are likely affecting course and outcomes of infected individuals.

Recently a novel type of highly virulent beta-coronavirus was discovered in patients with pneumonia of unknown cause. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) as detected by sequencing of the samples was found to be the cause of a severe respiratory disease in humans 1 Understanding the mechanism of action of the virus is a fundamental step in delineating the optimal therapeutic agents. Similar to SARS-CoV, SARS-Cov-2 enters the cell by the means of binding of cellular receptor(s) including the Angiotensin-converting enzyme 2 (ACE2) membrane bound protein 4 . ACE2 is a type I membrane protein expressed in lungs, heart, kidneys and intestine and decreased expression of ACE2 is associated with cardiovascular diseases 2,5 .

The structural basis for this recognition has been recently mapped out and the cryo-EM structure of the full length viral spike protein that targets human ACE2 complex has been reported 2 . The authors show that viral S protein binds ACE2 at least 10 times more tightly, when compared to the spike protein of the previous SARS-CoV strain. The viral spike glycoprotein (S protein) mediates receptor recognition 6 . Recently the 3.5-angstrom-resolution structure of the S protein has been described 6 . The S protein is cleaved into two subunits: S1 and S2. This cleavage of S protein by host proteases is critical for viral activation and subsequent infection 2 .

Host protease dependence of SARS-CoV-2 entry is a critical step. SARS-CoV takes advantage of the endosomal cysteine proteases Cathepsin B and L (CTSL and CTSB) 7 , 8 .

Cathepsin L is a peptidase that preferentially cleaves peptide bonds with aromatic residues in P2 and hydrophobic residues in P3 position 9 . CTSL is active at pH 3-6.5, in the presence of thiol and its enzymatic stability is dependent on ionic strength 9 . Cathepsin L proteolysis is a crucial mechanism for Ebola as well as SARS-CoV for processing of viral glycoprotein before cell membrane fusion 8 . Specifically, during cell membrane fusion the S protein is cleaved by host cell proteases, exposing a fusion peptide of the S2 domain. This leads to the fusion of viral and cellular membranes and the release of the viral genome into the cytoplasm of the host cell.

Cleavage of the S protein occurs between the S1 and S2 domains. Subsequently within the S2 domain additional cleavage (S2') occurs. S2' cleavage is responsible for unmasking and activating of the fusion peptide. Cleavage at both sites is believed to be necessary for viral entry by endocytosis into the host cell. The S1/S2 cleavage site of SARS-CoV-2 is between the threonine and methionine at positions 696 and 697. This S1/S2 cleavage site is identical to that 

To discover potential, pharmaceutical agents caable of affecting transcriptional expression levels We analyzed the expression profiles of CTSL across all 466 compounds tested. In order to find positive hits we selected only those results that showed a reduction of expression of CTSL (1.5fold difference). There were no drugs that would decrease CTSL expression by more than 40%.

Between the most 5 potent compounds (Table 1) were drugs from various therapeutic areasmuscle relaxer, antihistamine, anti-epileptic, anticholigenic and antiviral. These top results (top 5 of 466) included, Amantadine hydrochloride, a known and safe antiviral agent that was previously used to treat patients with influenza A.

Amantadine due to its high lipophilicity, can pass through lysosome membranes and accumulate in lysosomes acting at a higher micromolar concentrations as lysosomotropic alkalinizing agent 13, 14 . Amantadine inhibits influenza A replication at low micromolar concentration, by blocking M2 ion channel protein which acidifies virus interior and releases its nucleoprotein 13 , 14, 15 . It causes pH reduction which abrogates membrane fusion a necessary step for virus replication 13, 14 . Other lysosomotropic drugs affect lysosomes through lysosome membrane permeabilization and accumulation also blocking of Ca 2+ signaling, and enzyme activity inhibition or storage material accumulation 16 Since CTSL was not the top differentially expressed transcript, we decided to extend our analysis to all the genes that were downregulated by amantadine. Among the top 500 differentially expressed probes (383 genes, all with at least 50% expression reduction) we have found 21 genes were related to lysosomal terms using David Enrichment 19 tool (GO:005764, p=2.49x10 -5 ).

Moreover, the top significant pathway by ENRICHR enrichment analysis tool was KEGG lysosome pathway. Amantadine's significant effect upon lysosome pathway genes is shown on Figure 1 and Table 2 and Table 3 . Figure 1 displays notable difference in over-representation of genes with downregulated expression across lysosome pathway genes. Table 2 displays top lysosomal ontology terms over-represented among transcriptionally downregulated genes treated with amantadine. Table 3 

Decreasing the expression of CTSL is likely a potential mechanism that would lower the capacity of the virus to enter the next host cell. Another symbiotic, therapeutic mechanism is lysosomal pH modulationthat would further interfere with proteolytic Spike protein activation. 25 . The differences are primarily due to amino acid differences in NPC1 protein indicating that the heterogeneity of bat NPC1 orthologs is a crucial factor affecting varied degree of susceptibility 25 .

Interfering with the lysosomal milieu can have protective effects from coronavirus which we know uses Cathepsin L, a pH sensitive enzyme, to process the cleavage of the spike protein. Amantadine would be predicted by physical and chemical properties to accumulate in the lysosomes and raise pH, interfering with cathepsin L function. The gene expression pattern reported in this paper suggests that a more general lysosomal program is down-regulated by Amantadine, likely through a common set of transcription factors. Additionally, amantadine's property to accumulate in lysosomes, if effective, could reduce viral load, decrease intra-host organ spread and decrease individual-patient, associated disease severity and progression.

Importantly, the dose that was tested in High Throughput Screen Assay is within one order of magnitude of expected pharmacokinetic, clinical profile (~5uM). That would mean the drug can be administered per existing, safe and approved label dosing.

Further studies including clinical trials would be required in order to examine the role of amantadine administration as a treatment for COVID-19.

Drugs screening was carried out, the same one as applied in our previous study 26 

A Novel Coronavirus from Patients with Pneumonia in China

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Nextstrain: real-time tracking of pathogen evolution

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The Genotype-Tissue Expression (GTEx) project

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay

Proteolytic Enzym

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

Autoantibodies to angiotensinconverting enzyme 2 in patients with connective tissue diseases

Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A

Identification of the functional core of the influenza A virus A/M2 protonselective ion channel

Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function

The location of amantadine hydrochloride and free base within phospholipid multilayers: a neutron and X-ray diffraction study

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies

The BioMart community portal: an innovative alternative to large, centralized data repositories

Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure

Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes

COVID-19: faecal-oral transmission?

Genetic diseases conferring resistance to infectious diseases

Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression

Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism

We thank all the reviewers for valuable comments and suggestions